MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.yexcr.2026.115192

Медицинская библиотека · Experimental cell research · 2026

Recombinant Human Follicle-Stimulating Hormone Injection versus Gonal-f® in Controlled Ovarian Stimulation for Assisted Reproductive Technology: A Multicenter, Randomized, Assessor-Blind, Active-Controlled Phase III Trial.

Bai Haiyan, Li Jingjing, Wang Yang, Song Bing, Xu Xin, Sun Yongxin, Niu Qiuyun, Ma Caiyun, Xu Fan, Lin Jingjing, Cao Yunxia, Qiao Jie

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To evaluate the equivalence in the number of oocytes retrieved, as well as to compare the safety and immunogenicity between the recombinant human follicle-stimulating hormone injection (LZ-B-01) and Gonal-f® for controlled ovarian stimulation (COS) in assisted reproductive technology (ART).

METHODS

This multicenter, randomized, assessor-blind, active-controlled phase III trial enrolled 379 Chinese women with infertility undergoing ART. Participants were randomized to receive LZ-B-01 (n=189) or Gonal-f® (n=190). Subcutaneous injections were initiated on menstrual cycle day 2-3, with a fixed starting dose based on age and weight for the first five days, followed by dose adjustments according to ovarian response, with a maximum stimulation duration of up to 20 days. The primary endpoint was the number of oocytes retrieved 36±2 hours after trigger, with an equivalence margin set at ±3.0 oocytes. An ANCOVA model was fitted with treatment group as fixed effect, stratification factors and baseline antral follicle count (<15 vs. ≥15) as covariates. Secondary endpoints included gonadotropin dose, stimulation duration, follicular development, hormone levels, embryological/pregnancy outcomes, immunogenicity, and safety.

RESULTS

Baseline characteristics were balanced between groups. The least squares mean number of oocytes retrieved was 13.0 (95% CI: 12.1-13.9) in the LZ-B-01 group and 12.3 (95% CI: 11.4-13.2) in the Gonal-f® group, with a mean difference (LZ-B-01 minus Gonal-f®) of 0.7 oocytes (95% CI: -0.4 to 1.9), which fell entirely within the pre-specified equivalence margin of ±3.0 oocytes, confirming efficacy equivalence. Secondary efficacy endpoints, including gonadotropin dose, stimulation duration, embryological parameters, and pregnancy outcomes, were comparable between the the two groups. No treatment-emergent anti-drug antibodies were detected in either group. The incidence of treatment-emergent adverse events was comparable between the LZ-B-01 and Gonal-f® groups (59.6% vs. 60.0%).

CONCLUSION

LZ-B-01 demonstrated equivalent number of oocytes retrieved and a comparable safety profile to Gonal-f® for COS in ART, representing a suitable therapeutic alternative.

Для цитирования: Bai Haiyan, Li Jingjing, Wang Yang, Song Bing, Xu Xin, Sun Yongxin, Niu Qiuyun, Ma Caiyun, Xu Fan, Lin Jingjing, Cao Yunxia, Qiao Jie. Recombinant Human Follicle-Stimulating Hormone Injection versus Gonal-f® in Controlled Ovarian Stimulation for Assisted Reproductive Technology: A Multicenter, Randomized, Assessor-Blind, Active-Controlled Phase III Trial.. Experimental cell research. 2026. DOI: 10.1016/j.yexcr.2026.115192.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.